Use
OwnerMichael John Reed, Barry Victor Lloyd Potterinventors
Life of this patent
Estimating the term…
Abstract
There is provided use of a material selected from (i) microtubule stabilizing agent; (ii) microtubule disrupter; (iii) a compound of the formula A-B wherein A is an oxyhydrocarbyl group and B is a cyclic group; and (iv) a compound of the formula C-D wherein C is an sulphamate group and D is a cyclic group, for the manufacture of a medicament for the inhibition of tumor necrosis factor α (TNFα) stimulated aromatase activity.
Claims36
A composition for the inhibition of tumour necrosis factor α (TNFα) stimulated aromatase activity, wherein the composition comprises at least one of:
- (i) microtubule stabilising agent;
- (ii) microtubule disrupter;
- (iii) a compound of the formula A-B wherein A is an oxyhydrocarbyl group and B is a cyclic group;
- and
- (iv) a compound of the formula C-D wherein C is an sulphamate group and D is a cyclic group.
A method of making a composition for the inhibition of tumour necrosis factor α (TNFα) stimulated aromastase activity, wherein the composition comprises at least one of:
- (i) microtubule stabilising agent;
- (ii) microtubule disrupter;
- (iii) a compound of the formula A-B wherein A is an oxyhydrocarbyl group and B is a cyclic group;
- and
- (iv) a compound of the formula C-D wherein C is an sulphamate group and D is a cyclic group.
A pharmaceutical composition for the inhibition of tumour necrosis factor α (TNFα) stimulated aromatase activity, wherein the composition comprises at least one of:
- (i) microtubule stabilising agent;
- (ii) microtubule disrupter;
- (iii) a compound of the formula A-B wherein A is an oxyhydrocarbyl group and B is a cyclic group;
- and
- (iv) a compound of the formula C-D wherein C is an sulphamate group and D is a cyclic group.
A method of making a pharmaceutical composition for the inhibition of tumour necrosis factor a (TNFα) stimulated aromatase activity, wherein the composition comprises at least one of:
- (i) microtubule stabilising agent;
- (ii) microtubule disrupter;
- (iii) a compound of the formula A-B wherein A is an oxyhydrocarbyl group and B is a cyclic group;
- and
- (iv) a compound of the formula C-D wherein C is an sulphamate group and D is a cyclic group.
A method of treating a patient in need thereof, with the pharmaceutical composition for the inhibition of tumour necrosis factor α (TNFα) stimulated aromatase activity, wherein the composition comprises at least one of:
- (i) microtubule stabilising agent;
- (ii) microtubule disrupter;
- (iii) a compound of the formula A-B wherein A is an oxyhydrocarbyl group and B is a cyclic group;
- and
- (iv) a compound of the formula C-D wherein C is an sulphamate group and D is a cyclic group.
Dependencies are inferred from the claim text.